GGrantIndex
← Leaderboards

Uptal D Patel

Duke University

$4,543,116
Attributed
$4,719,929
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.4M · FY200616
$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16

Funding mix

By agency

NIH$4,719,929 · 4

By mechanism

R01$2,047,833 · 1
P30$1,641,405 · 1
K23$677,065 · 1
R34$353,626 · 1

Top collaborators

Most similar at Duke University

Same institution · by research overlap

Others in their field

Top investigators on “Kidney Diseases

Research focus

Kidney DiseasesRisk FactorsCardiovascular Disorder RiskTranslatingClinicResearch PersonnelLinkCardiovascular DiseasesClinical ResearchMultidisciplinaryAspirinBlood PressureCardiovascular SystemGlomerular Filtration RateDiabetes MellitusEventRenal FunctionTranslationsRandomized Controlled TrialsHypertensionBaseChronic Kidney FailureProgramsPharmaceutical Preparations

Grant awards (15)

Clinical and Translational Research Core$328,281
P30 · FY2016 · DK · contact PI
Multi-factorial Intervention to Slow Progression of Diabetic Kidney Disease$682,611
R01 · FY2015 · DK · contact PI
Clinical and Translational Research Core$328,281
P30 · FY2015 · DK · contact PI
Multi-factorial Intervention to Slow Progression of Diabetic Kidney Disease$682,611
R01 · FY2014 · DK · contact PI
Integrated Population Program for Diabetic Kidney Disease$353,626
R34 · FY2014 · DK · contact PI
Clinical and Translational Research Core$328,281
P30 · FY2014 · DK · contact PI
Multi-factorial Intervention to Slow Progression of Diabetic Kidney Disease$682,611
R01 · FY2013 · DK · contact PI
Clinical and Translational Research Core$328,281
P30 · FY2013 · DK · contact PI
Clinical and Translational Research Core$328,281
P30 · FY2012 · DK · contact PI
Barriers to Optimal Cardiovascular Medication Use in Diabetes and Renal Disease$125,213
K23 · FY2010 · DK · contact PI
Barriers to Optimal Cardiovascular Medication Use in Diabetes and Renal Disease$125,213
K23 · FY2009 · DK · contact PI
Barriers to Optimal Cardiovascular Medication Use in Diabetes and Renal Disease$50,000
K23 · FY2009 · DK · contact PI
Barriers to Optimal Cardiovascular Medication Use in Diabetes and Renal Disease$126,213
K23 · FY2008 · DK · contact PI
Barriers to Optimal Cardiovascular Medication Use in Diabetes and Renal Disease$125,213
K23 · FY2007 · DK · contact PI
Barriers to Optimal Cardiovascular Medication Use in Diabetes and Renal Disease$125,213
K23 · FY2006 · DK · contact PI